The purpose of the study is to evaluate the immunological response and tolerance of 3 vaccine strategies against meningococcus B, a potentially fatal invasive infection.
Male or female, >=18 to <=75 years old.
Asplenic patient (for at least 2 weeks) with Howell Jolly bodies visible on blood film
Splenectomy confirmed by consultation and/or hospitalization report or the ultrasound if it has been performed during the routine follow-up
Women of childbearing age must have an effective contraception during the first 9 months of the study.
History of meningococcal vaccination B.
History of anaphylaxis post vaccination.
Known allergy to any components (active substances or excipients) of both vaccines.
Patients who cannot stop antibiotics 3 days before blood collection.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
EUCLID Clinical Trial Platform
Collaborator
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Collaborator
CIC 1417 Cochin-Pasteur
Collaborator
Innovative clinical research in vaccinologie (I-REIVAC)
Collaborator
Institut Pasteur
Collaborator
URC-CIC Paris Descartes Necker Cochin
Collaborator